Antineoplastic drug screening cell model utilizing STAT3 as target and creation and application thereof

Abstract

The invention provides an antineoplastic drug screening cell model utilizing STAT3 as target, belonging to the field of biomedicine. The model is created by a reporting system carrier containing an STAT3 specific binding sequence on the basis of active cells with constitutive STAT3, and the model is used for screening treatment medicine of carcinomatous changes and tumors caused by STAT3 constitutive activation. The active cells with the constitutive STAT3 are utilized, so the reporter gene in the model cell is situated at an overactive state, and no additional stimulant is necessary; besides, the obtained stable cell model can be directly used for screening the compounds, thereby not only greatly reducing the screening cost, but also simplifying the whole screening process from cell cultivation, STAT3 activation, compound feed and detection to cell cultivation, compound feed and detection, shortening the screening period, reducing the operation steps, and improving the stability, efficiency and usability of the system, so that the model is more suitable for high throughput medicine screening.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a cell model for screening anti-tumor drugs targeting STAT3, in particular to a cell model for screening anti-tumor drugs based on cells with constitutive STAT3 activity; the invention also relates to the Construction method and application of cell model for anti-tumor drug screening. Background technique [0002] Signal transducer and activator of transcription 3 (STAT3), as an important transcription factor, plays an important role in the occurrence and development of cancer, and is recognized as a cancer-related protein. In many tumor cells, such as colon cancer, breast cancer, glioma cells, lung cancer, head and neck cancer, etc., STAT3 often exists in a continuously activated form, and STAT3 is stimulated by upstream signaling cytokines or in some In the state of continuous activation of tyrosine kinase, its C-terminal tyrosine 705 is phosphorylated to form a dimer, and then enters...

AI Technical Summary

Problems solved by technology

[0003] The current drug screening system based on the STAT3 target usually has disadvantages such as low efficiency and cumbersome steps. For example, exogenous cytokines such as interleukin 6 (IL-6) and leukocyte inhibitory factor (LIF) are required to activate each drug screening. Intracellular STAT3, additional steps will greatly reduce the stability of the drug screening system, and the cost will be greatly increased due to the use of IL-6 or LIF

Images